Title |
The rise of carbapenem resistance in Europe: just the tip of the iceberg?
|
---|---|
Published in |
Antimicrobial Resistance & Infection Control, February 2013
|
DOI | 10.1186/2047-2994-2-6 |
Pubmed ID | |
Authors |
Anna-Pelagia Magiorakos, Carl Suetens, Dominique L Monnet, Carlo Gagliotti, Ole E Heuer, EARS-Net Coordination Group and EARS-Net participants |
Abstract |
The European Antimicrobial Resistance Surveillance Network (EARS-Net) collects data on carbapenem resistance from invasive bacterial infections. Increasing percentages of carbapenem resistance in K. pneumoniae isolates were reported from progressively more countries in Europe between 2005 and 2010. A trend analysis showed increasing trends for Greece, Cyprus, Hungary and Italy (p < 0.01). EARS-Net collects data on invasive bacterial isolates, which likely correspond to a fraction of the total number of infections. Increasing reports of community cases suggest that dissemination of carbapenem-resistant K. pneumoniae has penetrated into the community. Good surveillance and infection control measures are urgently needed to contain this spread. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 25% |
Canada | 1 | 25% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Poland | 1 | 1% |
Unknown | 84 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 19 | 22% |
Student > Ph. D. Student | 13 | 15% |
Student > Master | 13 | 15% |
Student > Doctoral Student | 7 | 8% |
Student > Bachelor | 4 | 5% |
Other | 13 | 15% |
Unknown | 16 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 31 | 36% |
Agricultural and Biological Sciences | 9 | 11% |
Biochemistry, Genetics and Molecular Biology | 7 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Immunology and Microbiology | 4 | 5% |
Other | 9 | 11% |
Unknown | 21 | 25% |